
GoodRx Holdings (GDRX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
203.0M
Gross Profit
189.6M
93.42%
Operating Income
23.4M
11.52%
Net Income
11.1M
5.45%
EPS (Diluted)
$0.03
Balance Sheet Metrics
Total Assets
1.3B
Total Liabilities
640.9M
Shareholders Equity
654.3M
Debt to Equity
0.98
Cash Flow Metrics
Operating Cash Flow
37.6M
Free Cash Flow
-12.5M
Revenue & Profitability Trend
GoodRx Holdings Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 792.3M | 750.3M | 766.6M | 745.4M | 550.7M |
Cost of Goods Sold | 48.2M | 66.9M | 65.1M | 46.7M | 29.6M |
Gross Profit | 744.1M | 683.3M | 701.5M | 698.7M | 521.1M |
Gross Margin % | 93.9% | 91.1% | 91.5% | 93.7% | 94.6% |
Operating Expenses | |||||
Research & Development | 123.7M | 135.8M | 143.1M | 125.9M | 61.8M |
Selling, General & Administrative | 485.0M | 466.8M | 502.4M | 524.9M | 716.6M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 608.7M | 602.7M | 645.6M | 650.8M | 778.4M |
Operating Income | 65.8M | -27.0M | 1.7M | 13.4M | -275.7M |
Operating Margin % | 8.3% | -3.6% | 0.2% | 1.8% | -50.1% |
Non-Operating Items | |||||
Interest Income | 23.3M | 32.2M | 9.3M | 59.0K | 160.0K |
Interest Expense | 52.9M | 56.7M | 34.2M | 23.6M | 27.9M |
Other Non-Operating Income | -4.7M | -4.0M | - | - | 22.0K |
Pre-tax Income | 31.5M | -55.6M | -23.2M | -10.2M | -303.4M |
Income Tax | 15.1M | -46.7M | 9.6M | 15.1M | -9.8M |
Effective Tax Rate % | 47.9% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | 16.4M | -8.9M | -32.8M | -25.3M | -293.6M |
Net Margin % | 2.1% | -1.2% | -4.3% | -3.4% | -53.3% |
Key Metrics | |||||
EBITDA | 156.0M | 108.8M | 65.2M | 48.0M | -257.1M |
EPS (Basic) | $0.04 | $-0.02 | $-0.08 | $-0.06 | $-1.07 |
EPS (Diluted) | $0.04 | $-0.02 | $-0.08 | $-0.06 | $-1.07 |
Basic Shares Outstanding | 385737000 | 410315000 | 412858000 | 409981000 | 274696000 |
Diluted Shares Outstanding | 385737000 | 410315000 | 412858000 | 409981000 | 274696000 |
Income Statement Trend
GoodRx Holdings Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 448.3M | 672.3M | 757.2M | 941.1M | 968.7M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 145.9M | 143.6M | 117.1M | 118.1M | 68.7M |
Inventory | - | - | - | - | - |
Other Current Assets | 50.1M | 40.4M | 35.1M | 21.3M | 17.5M |
Total Current Assets | 659.3M | 872.8M | 919.7M | 1.1B | 1.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 27.8M | 29.9M | 35.9M | 27.7M | 27.7M |
Goodwill | 998.4M | 977.9M | 1.0B | 793.2M | 579.0M |
Intangible Assets | 176.9M | 156.3M | 189.9M | 133.8M | 56.7M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 100.7M | 103.0M | 27.2M | 6.0M | 15.1M |
Total Non-Current Assets | 728.8M | 716.0M | 684.9M | 518.8M | 383.7M |
Total Assets | 1.4B | 1.6B | 1.6B | 1.6B | 1.5B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 14.1M | 36.3M | 17.7M | 17.5M | 10.3M |
Short-term Debt | 10.6M | 15.0M | 11.1M | 12.9M | 11.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 15.8M | - | - | - | - |
Total Current Liabilities | 123.9M | 122.6M | 76.3M | 81.1M | 59.6M |
Non-Current Liabilities | |||||
Long-term Debt | 532.8M | 696.1M | 705.9M | 689.4M | 693.4M |
Deferred Tax Liabilities | - | - | - | 244.0K | 0 |
Other Non-Current Liabilities | 6.8M | 8.2M | 7.6M | 5.4M | 5.8M |
Total Non-Current Liabilities | 539.5M | 704.3M | 713.5M | 694.8M | 699.2M |
Total Liabilities | 663.4M | 826.8M | 789.8M | 775.9M | 758.8M |
Equity | |||||
Common Stock | 38.0K | 40.0K | 40.0K | 40.0K | 39.0K |
Retained Earnings | -1.4B | -1.5B | -1.4B | -1.4B | -1.4B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 724.7M | 762.0M | 814.8M | 831.7M | 711.4M |
Key Metrics | |||||
Total Debt | 543.4M | 711.1M | 717.0M | 702.3M | 704.9M |
Working Capital | 535.4M | 750.2M | 843.4M | 1.0B | 1.0B |
Balance Sheet Composition
GoodRx Holdings Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 16.4M | -8.9M | -32.8M | -25.3M | -293.6M |
Depreciation & Amortization | 69.5M | 107.7M | 54.2M | 34.5M | 18.4M |
Stock-Based Compensation | 99.0M | 104.8M | 120.2M | 160.5M | 397.3M |
Working Capital Changes | -29.9M | -11.0M | -1.4M | -42.9M | -3.7M |
Operating Cash Flow | 149.8M | 139.9M | 164.5M | 146.3M | 159.2M |
Investing Activities | |||||
Capital Expenditures | -1.2M | -1.0M | -4.0M | -4.6M | -20.6M |
Acquisitions | 0 | 0 | -155.3M | -144.3M | -55.8M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -1.2M | -1.0M | -159.3M | -148.8M | -76.3M |
Financing Activities | |||||
Share Repurchases | -158.8M | -104.0M | -101.7M | 0 | 0 |
Dividends Paid | - | - | - | - | 0 |
Debt Issuance | 472.0M | - | 0 | 0 | 28.0M |
Debt Repayment | -639.0M | -5.3M | -7.0M | -7.0M | -35.0M |
Financing Cash Flow | -358.3M | -174.7M | -129.4M | -65.5M | 899.8M |
Free Cash Flow | 113.5M | 82.5M | 91.6M | 144.3M | 95.5M |
Net Change in Cash | -209.8M | -35.9M | -124.1M | -68.1M | 982.6M |
Cash Flow Trend
GoodRx Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
51.89
Forward P/E
11.39
Price to Book
2.53
Price to Sales
2.03
PEG Ratio
0.52
Profitability Ratios
Profit Margin
4.33%
Operating Margin
13.20%
Return on Equity
5.27%
Return on Assets
5.08%
Financial Health
Current Ratio
4.21
Debt to Equity
85.15
Beta
1.24
Per Share Data
EPS (TTM)
$0.09
Book Value per Share
$1.84
Revenue per Share
$2.12
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
gdrx | 1.6B | 51.89 | 2.53 | 5.27% | 4.33% | 85.15 |
Veeva Systems | 46.5B | 60.37 | 7.46 | 14.06% | 27.34% | 1.24 |
Ge Healthcare | 33.5B | 15.03 | 3.45 | 25.80% | 11.22% | 107.67 |
Certara | 1.8B | 223.60 | 1.68 | 0.75% | 1.97% | 29.00 |
10x Genomics | 1.7B | -8.79 | 2.17 | -11.30% | -13.13% | 11.22 |
Schrodinger | 1.5B | 44.39 | 4.30 | -44.40% | -76.22% | 33.38 |
Financial data is updated regularly. All figures are in the company's reporting currency.